AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$GILD

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Gilead (GILD) reported Q3 earnings, with total product sales of $8.29B, beating the $7.75B estimate. Key segments like HIV and liver disease products saw significant growth, while oncology and royalty revenues fell short of expectations.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 1:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GILDBullishHigh
01

Why it matters

The earnings beat and robust product sales suggest a positive catalyst for Gilead and potentially for the broader biotech sector.

02

Market read

Earnings beat could drive a rally in Gilead and lift related biotech stocks.

03

What to watch

Weakness in royalty income and underperformance of oncology product Yescarta may offset the revenue beat.

Relevance 10/10Novelty 9/10Timing: after-hours release

Background

Gilead Sciences reported Q3 earnings, beating revenue estimates with $8.29B total sales, driven by strong HIV and liver disease product performance.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

Q3 earnings report shows product sales beating analyst estimates across HIV and liver disease segments.

Expected impact

likely upward pressure as the market prices in the earnings beat and strong product performance

Evidence & confidence

Revenue beat and double‑digit growth in core drugs suggest upside potential for the stock.

Market effects

Sector

Biotech and pharma sector may benefit from Gilead's strong HIV drug sales and revenue beat.

Regional

U.S. healthcare stocks could see a lift following the earnings surprise.

Global

Global biotech investors may view the results as a positive signal for similar companies.

Counterpoint

What could challenge this read

Decline in royalty revenue and a drop in Yescarta cell‑therapy sales could weigh on the stock.

Key entities

  • company
    Gilead Sciences

    US‑listed biopharma company reporting Q3 earnings.

Read at source← All news

StoryGilead beats Q3 2026 earnings, lifts full‑year sales outlook on strong HIV growth

Also covered by

6 outlets

Related articles

OCT 30
$GILDMedAI 8/10

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead Sciences (GILD) raised its 2026 sales outlook to $31B-$31.3B, citing strong Q3 growth. HIV revenues are expected to grow 12% in 2026, but Biktarvy faces a $1.5B revenue headwind in 2028 due to Medicare pricing. Q3 earnings beat estimates at $2.55 per share, with revenues of $8.3B. The company also detailed advancements in oncology and inflammation pipelines.

zacks.com3 min
OCT 30
$GILDHighAI 9/10

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead Sciences reported Q3 2026 adjusted earnings of $2.55 per share, beating estimates. Revenues rose 6.8% to $8.3B, driven by HIV drugs and Trodelvy. HIV sales grew 18% to $6.25B, while Trodelvy sales jumped 42% to $506M. GILD raised its 2026 product sales guidance to $31-$31.3B. Cell Therapy revenues declined 18% to $355M. Shares have gained 38.2% year to date.

zacks.com6 min